Cost Effectiveness of Tobramycin Versus Azithromycin as First-Line Therapy for Acute Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1594
https://www.valueinhealthjournal.com/article/S1098-3015(18)31900-4/fulltext
Title :
Cost Effectiveness of Tobramycin Versus Azithromycin as First-Line Therapy for Acute Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31900-4&doi=10.1016/j.jval.2018.04.1594
First page :
Section Title :
Open access? :
No
Section Order :
823